JP2017531682A - 医薬製剤の粘度低下 - Google Patents

医薬製剤の粘度低下 Download PDF

Info

Publication number
JP2017531682A
JP2017531682A JP2017522169A JP2017522169A JP2017531682A JP 2017531682 A JP2017531682 A JP 2017531682A JP 2017522169 A JP2017522169 A JP 2017522169A JP 2017522169 A JP2017522169 A JP 2017522169A JP 2017531682 A JP2017531682 A JP 2017531682A
Authority
JP
Japan
Prior art keywords
viscosity
excipient
protein
concentration
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017522169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531682A5 (enExample
Inventor
スローイー，クリストファー・ジェイムズ
カナプラン，セカール
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2017531682(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2017531682A publication Critical patent/JP2017531682A/ja
Publication of JP2017531682A5 publication Critical patent/JP2017531682A5/ja
Priority to JP2019191701A priority Critical patent/JP6965321B2/ja
Priority to JP2021170676A priority patent/JP7411615B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017522169A 2014-10-23 2015-10-22 医薬製剤の粘度低下 Pending JP2017531682A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019191701A JP6965321B2 (ja) 2014-10-23 2019-10-21 医薬製剤の粘度低下
JP2021170676A JP7411615B2 (ja) 2014-10-23 2021-10-19 医薬製剤の粘度低下

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462067637P 2014-10-23 2014-10-23
US62/067,637 2014-10-23
PCT/US2015/056972 WO2016065181A1 (en) 2014-10-23 2015-10-22 Reducing viscosity of pharmaceutical formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019191701A Division JP6965321B2 (ja) 2014-10-23 2019-10-21 医薬製剤の粘度低下

Publications (2)

Publication Number Publication Date
JP2017531682A true JP2017531682A (ja) 2017-10-26
JP2017531682A5 JP2017531682A5 (enExample) 2018-09-27

Family

ID=54427875

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017522169A Pending JP2017531682A (ja) 2014-10-23 2015-10-22 医薬製剤の粘度低下
JP2019191701A Active JP6965321B2 (ja) 2014-10-23 2019-10-21 医薬製剤の粘度低下
JP2021170676A Active JP7411615B2 (ja) 2014-10-23 2021-10-19 医薬製剤の粘度低下

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019191701A Active JP6965321B2 (ja) 2014-10-23 2019-10-21 医薬製剤の粘度低下
JP2021170676A Active JP7411615B2 (ja) 2014-10-23 2021-10-19 医薬製剤の粘度低下

Country Status (17)

Country Link
US (3) US11813328B2 (enExample)
EP (2) EP3909611B1 (enExample)
JP (3) JP2017531682A (enExample)
KR (1) KR102534017B1 (enExample)
CN (2) CN107206070B (enExample)
AU (2) AU2015335743B2 (enExample)
BR (1) BR112017008125B1 (enExample)
CA (1) CA2964786C (enExample)
CL (2) CL2017000984A1 (enExample)
EA (3) EA033444B1 (enExample)
ES (1) ES2964713T3 (enExample)
IL (2) IL287947B2 (enExample)
MA (1) MA54716A (enExample)
MX (2) MX388858B (enExample)
SG (1) SG11201703152RA (enExample)
WO (1) WO2016065181A1 (enExample)
ZA (1) ZA201702762B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023513312A (ja) * 2020-02-13 2023-03-30 アムジェン インコーポレイテッド ヒト抗ｔｓｌｐ抗体の製剤及び炎症性疾患を治療する方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2964713T3 (es) 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
MA46466A (fr) 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite
JP7377596B2 (ja) * 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
WO2018200533A1 (en) 2017-04-28 2018-11-01 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
AU2018258676B2 (en) * 2017-04-28 2024-09-19 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
SG11202003754YA (en) 2017-05-16 2020-05-28 Bhamis Research Laboratory Pvt Ltd High concentration protein formulations with reduced viscosity
PE20200678A1 (es) 2017-06-16 2020-06-11 Zealand Pharma As Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2)
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
WO2019106206A1 (en) 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
BR112020026492A2 (pt) 2018-07-05 2021-04-06 Bayer Aktiengesellschaft Método para a produção de péletes liofilizados compreendendo um anticorpo antifator de coagulação xia (fxia)
KR20210052389A (ko) 2018-08-27 2021-05-10 리제너론 파마슈티칼스 인코포레이티드 다운스트림 정제에서의 라만 분광법의 사용
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
WO2020219550A1 (en) * 2019-04-23 2020-10-29 Amgen Inc. The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations
KR102746418B1 (ko) * 2020-12-03 2024-12-26 동국대학교 산학협력단 N-아세틸-l-아르기닌을 포함하는 단백질 응집 억제용 조성물
WO2022191550A1 (ko) * 2021-03-09 2022-09-15 (주)지아이이노베이션 ＩｇＥ Ｆｃ 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 융합단백질의 제형
CN117355321A (zh) * 2021-04-09 2024-01-05 安万托特性材料股份有限公司 增强性能的赋形剂以及降低生物制剂的粘度和提高生物制剂的稳定性的方法
WO2025175164A1 (en) * 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522814A (ja) * 1997-11-07 2001-11-20 カイロン コーポレイション 増大されたｉｇｆ−ｉ溶解性を提供する組成物
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
JP2011067202A (ja) * 2009-08-31 2011-04-07 Sanyo Chem Ind Ltd タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及びタンパク質の安定化方法
JP2013525484A (ja) * 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
US20130171128A1 (en) * 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6159485A (en) * 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
AU4458401A (en) 2000-03-31 2001-10-15 Kirin Brewery Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability
US6994847B2 (en) 2000-11-07 2006-02-07 Chiron Corporation Stabilized interferon compositions
AU2002332628B2 (en) 2001-08-23 2007-07-26 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
MXPA04008215A (es) 2002-02-27 2004-11-26 Immunex Corp Formulacion polipeptidica.
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
CA2512174A1 (en) 2003-01-30 2004-08-12 Christian B. Allan Anti-integrin .alpha..nu..beta.3 antibody formulations and uses thereof
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
EP2170957A1 (en) 2007-06-20 2010-04-07 Irm, Llc Methods and compositions for treating allergic diseases
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
JP5840364B2 (ja) * 2007-11-30 2016-01-06 アッヴィ バイオテクノロジー リミテッド タンパク質製剤及びその製造方法
CA2711984A1 (en) * 2008-01-15 2009-07-23 Abbott Gmbh & Co. Kg Powdered protein compositions and methods of making same
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
BR112012011539A8 (pt) * 2009-11-17 2017-12-26 Ipsen Pharma Sas formulação para a combinação de hgh e rhigf-1
CA2788863C (en) * 2010-02-04 2020-07-07 Reinhard Franz Bolli Immunoglobulin preparation
EP3409289B1 (en) * 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EP2735315B1 (en) 2011-07-19 2019-10-02 Chugai Seiyaku Kabushiki Kaisha Stable protein-containing preparation containing argininamide or valinamide
WO2013063510A1 (en) * 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US20150150982A1 (en) 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
US20150004174A1 (en) 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
ES2964713T3 (es) 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
AU2015357068B2 (en) 2014-12-03 2021-07-29 Csl Behring Ag Pharmaceutical product with increased stability comprising immunoglobulins
SG10201912565QA (en) 2016-09-29 2020-02-27 Amgen Inc Low-viscosity antigen binding proteins and methods of making them
MA46466A (fr) 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522814A (ja) * 1997-11-07 2001-11-20 カイロン コーポレイション 増大されたｉｇｆ−ｉ溶解性を提供する組成物
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
JP2011067202A (ja) * 2009-08-31 2011-04-07 Sanyo Chem Ind Ltd タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及びタンパク質の安定化方法
US20130171128A1 (en) * 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations
JP2013525484A (ja) * 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023513312A (ja) * 2020-02-13 2023-03-30 アムジェン インコーポレイテッド ヒト抗ｔｓｌｐ抗体の製剤及び炎症性疾患を治療する方法

Also Published As

Publication number Publication date
MX2017005243A (es) 2017-08-18
ES2964713T3 (es) 2024-04-09
JP2020037559A (ja) 2020-03-12
EA038462B1 (ru) 2021-08-31
EP3209332A1 (en) 2017-08-30
IL287947B1 (en) 2024-04-01
MA54716A (fr) 2021-11-17
EA201790787A1 (ru) 2017-08-31
SG11201703152RA (en) 2017-05-30
JP2022009223A (ja) 2022-01-14
IL287947B2 (en) 2024-08-01
EP3909611B1 (en) 2023-08-30
AU2021200990A1 (en) 2021-03-11
ZA201702762B (en) 2022-12-21
CN114569716A (zh) 2022-06-03
EA033444B1 (ru) 2019-10-31
BR112017008125A2 (pt) 2018-06-19
US20240066124A1 (en) 2024-02-29
EA202191513A1 (ru) 2021-11-30
US12318447B2 (en) 2025-06-03
AU2015335743B2 (en) 2020-12-24
IL287947A (en) 2022-01-01
CL2019002190A1 (es) 2019-11-22
IL251726B (en) 2021-12-01
JP6965321B2 (ja) 2021-11-10
EP3909611A1 (en) 2021-11-17
MX388858B (es) 2025-03-20
MX2021015789A (es) 2022-01-27
CL2017000984A1 (es) 2018-01-05
JP7411615B2 (ja) 2024-01-11
AU2015335743A1 (en) 2017-05-04
KR102534017B1 (ko) 2023-05-19
US20250345421A1 (en) 2025-11-13
KR20170071518A (ko) 2017-06-23
WO2016065181A1 (en) 2016-04-28
CA2964786C (en) 2023-10-17
AU2021200990B2 (en) 2023-02-16
EA201991447A1 (ru) 2019-11-29
CA2964786A1 (en) 2016-04-28
CN107206070B (zh) 2022-01-18
IL251726A0 (en) 2017-06-29
US20170333559A1 (en) 2017-11-23
EP3209332B1 (en) 2021-05-26
CN107206070A (zh) 2017-09-26
US11813328B2 (en) 2023-11-14
BR112017008125B1 (pt) 2023-11-21

Similar Documents

Publication Publication Date Title
JP7411615B2 (ja) 医薬製剤の粘度低下
US20200276313A1 (en) Pharmaceutical Formulations
US20130171128A1 (en) Reducing viscosity of pharmaceutical formulations
JP2019530703A (ja) 粘度低下タンパク質医薬製剤
HK1242572B (en) Reducing viscosity of pharmaceutical formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180814

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190717

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191217